Methyltestosterone interactions

CONTRAINDICATIONS: Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG. (Chorionic gonadotropin label, Contraindications)

These drugs include, but are not limited to, the following: the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin the androgen receptor inhibitor enzalutamide the antimycobacterials rifampin, rifapentine the cytotoxic agent mitotane St. (Doravirine label, Contraindications)

Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant female who receives finasteride. (Finasteride label, Contraindications)

To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use. (Methyltestosterone label, Warnings)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Methyltestosterone label, Drug interactions)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Methyltestosterone label, Drug interactions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Methyltestosterone label, Drug interactions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

PRECAUTIONS General Induction of androgen secretion by hCG may cause fluid retention. (Choriogonadotropin alfa label, Precautions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (Conjugated estrogens label, Precautions)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (Conjugated estrogens and bazedoxifene label, Warnings and precautions)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Methyltestosterone label, Drug interactions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Methyltestosterone label, Drug interactions)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Methyltestosterone label, Drug interactions)

Free hormone concentrations, such as testosterone and estradiol, may be decreased. (Estradiol and norethindrone label, Warnings and precautions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

For Men : Clinical monitoring for spermatogenesis utilizes the following indirect or direct measures: Serum testosterone level Semen analysis 5.11 FOLLISTIM Pen The FOLLISTIM Pen is intended only for use with FOLLISTIM AQ Cartridge. (Follitropin label, Warnings and precautions)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Methyltestosterone label, Drug interactions)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (Glimepiride label, Drug interactions)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (Goserelin label, Warnings and precautions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Methyltestosterone label, Drug interactions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Methyltestosterone label, Drug interactions)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Methyltestosterone label, Drug interactions)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Methyltestosterone label, Drug interactions)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Methyltestosterone label, Drug interactions)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Methyltestosterone label, Drug interactions)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Methyltestosterone label, Drug interactions)

Tumor Flare: Increased serum testosterone (~ 50% above baseline) may occur when initiating treatment with LUPRON DEPOT. (Leuprolide label, Warnings and precautions)

Androgens/Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nictonic Acid These drugs may decrease serum TBG concentration. (Levothyroxine label, Drug interactions)

Androgens/Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid These drugs may decrease serum TBG concentration. (Liothyronine label, Drug interactions)

However, clinical studies have shown that lovastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve, and does not reduce basal plasma testosterone concentration. (Lovastatin label, Drug interactions)

The following laboratory tests may be affected by progestins including MPA Injectable Suspension, USP: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol). (Medroxyprogesterone label, Drug interactions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

…anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs… (Pioglitazone and glimepiride label, Drug interactions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Reproductive effects: Include decreased testosterone and increased prolactin levels. (Ramelteon label, Warnings and precautions)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Methyltestosterone label, Drug interactions)

Abiraterone: Spironolactone binds to the androgen receptor and may increase prostate‑specific antigen (PSA) levels in abiraterone-treated prostate cancer patients. (Spironolactone and hydrochlorothiazide label, Drug interactions)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (Tamoxifen label, Warnings and precautions)

Insulin: In diabetic patients the metabolic effects of androgens may decrease blood glucose and insulin requirements. (Methyltestosterone label, Drug interactions)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (Methyltestosterone label, Warnings)

Tumor Flare: Transient increase in serum testosterone levels can occur within the first few weeks of treatment. (Triptorelin label, Warnings and precautions)

DRUG INTERACTIONS Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. (Methyltestosterone label, Drug interactions)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Methyltestosterone label, Precautions)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Methyltestosterone label, Precautions)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Methyltestosterone label, Precautions)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Methyltestosterone label, Precautions)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)

In addition to discontinuation of the drug, diuretic therapy may be required. (Methyltestosterone label, Warnings)